CHENGDU – April 17, 2023 (XYZ Newswire) Technoderma Medicines, Inc. (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the Company has begun dosing patients in its Androgenetic Alopecia (AGA) Phase 2 clinical trial of t
On February 8, 2023(PT, UTC-8), TechnoDermaMedicines Inc.(hereinafter referred to as "TechnoDerma"), which focuses on the R&Dof new topicaldrugs, officially announced that it had initiatedthe phase I clinical trial of its TDM-180935 topical
On January 13, TechnoDermaannounced that it has recently completed a series A+ financing of tens of millions of RMB. Benefit fromthe capital market's favor and high recognition of the company's hair and eczema dermatitis clinical pipelines, the co
On Aug 9th, 2022, US Pacific Time, Technoderma Medicines (TDM), a drug discovery startup specialized in dermatology indications based at Jiaxing, China,announced that FDA approved the IND application of its novel experimental drug for the topical treatmen
Technoderma Medicines, Inc., a clinical stage biopharmaceutical company, is pleased to report the Company has begun dosing in its Phase 1b (MAD) clinical trial of topical TDM-105795 solution in patients with Androgenetic Alopecia (AGA).
Technoderma Medicines, Inc. is a privately held clinical stage biopharmaceutical company. The Company was originally locatedin Jiaxing Xiuzhou Biomedicine Guoqian Park, China,and recently relocated to Chengdu Biomed Town, Chengdu, Sichuan Province, China.
Its current core programs focus on development of innovative therapies for Androgenetic Alopecia, Atopic Dermatitis, Psoriasis and Lupus Erythematosus. Its "first-in-class" small molecule thyromimetic drug candidate TDM-105795 for Androgenetic Alopecia is currently in Phase 2a clinical testing. Technoderma’s novel JAK1/TYK2 inhibitor TDM-180935 for Atopic Dermatitis is now in Phase 1 clinical testing. The pipeline targets dermatologic indications.
